Prognostic and Predictive Biomarkers in the Era of Immunotherapy for Lung Cancer.

Fiche publication

Date publication

avril 2023

Journal

International journal of molecular sciences

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BEAU-FALLER Michèle , Dr PENCREACH Erwan , Pr MASCAUX Céline

Tous les auteurs :
Pabst L, Lopes S, Bertrand B, Creusot Q, Kotovskaya M, Pencreach E, Beau-Faller M, Mascaux C

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/37108738

Résumé

The therapeutic algorithm of lung cancer has recently been revolutionized by the emergence of immune checkpoint inhibitors. However, an objective and durable response rate remains low with those recent therapies and some patients even experience severe adverse events. Prognostic and predictive biomarkers are therefore needed in order to select patients who will respond. Nowadays, the only validated biomarker is the PD-L1 expression, but its predictive value remains imperfect, and it does not offer any certainty of a sustained response to treatment. With recent progresses in molecular biology, genome sequencing techniques, and the understanding of the immune microenvironment of the tumor and its host, new molecular features have been highlighted. There are evidence in favor of the positive predictive value of the tumor mutational burden, as an example. From the expression of molecular interactions within tumor cells to biomarkers circulating in peripheral blood, many markers have been identified as associated with the response to immunotherapy. In this review, we would like to summarize the latest knowledge about predictive and prognostic biomarkers of immune checkpoint inhibitors efficacy in order to go further in the field of precision immuno-oncology.